http://www.acc.org/Feed?clinicalTopicID=8e0665e1-fe1f-4915-88f0-f894baeef01f Clinical Topic Feed: Pulmonary Hypertension en /Latest-in-Cardiology/Articles/2026/08/29/08/48/sun-324am-padn-esc-2026 Pulmonary-artery denervation, in addition to guideline-directed medical therapy, resulted in fewer events of clinical worsening than medical therapy alone in patients with pulmonary hypertension associated with left heart disease and heart failure (HF), based on findings from the PADN-HF-PH trial presented at ESC Congress 2026 and simultaneously published in NEJM. 1788082020000 Articles and Stories /Latest-in-Cardiology/Articles/2022/10/31/13/02/Clinical-Practice-Algorithm-For-the-Follow-Up-of-Unrepaired-and-Repaired-PDA Isolated patent ductus arteriosus (PDA) is a relatively common defect, accounting for 5-10% of congenital heart defects (excluding premature infants).1 Given the increased use of echocardiography, incidental detection of asymptomatic silent PDAs is on the rise. 1787745300000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/08/03/10/06/ADVANCE-OUTCOMES Ralinepag, a selective prostacyclin IP receptor agonist, significantly reduced the risk of first clinical worsening compared with placebo in patients with pulmonary arterial hypertension (PAH) but was associated with more adverse-event-related treatment discontinuations, according to results of the ADVANCE OUTCOMES trial published July 28 in The Lancet. 1785862800000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/02/12/49/accel-lite-02jun2026 In this interview, Clyde W. Yancy MD, MACC and Mardi Gomberg-Maitland, MD, MSc, FACC discuss the CADENCE Trial (Efficacy And Safety Of Sotatercept In Combined Post-and Pre-capillary Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction). 1780414200000 Articles and Stories /Latest-in-Cardiology/Articles/2026/05/01/01/Journal-Wrap The hottest research from various peer-reviewed journals – handpicked weekly by the ACC. 1777637340000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/27/19/07/Heart-Failure-Trials-Featured-at-ACC26 ACC.26 featured several late-breaking heart failure clinical trials, including two focused on subgroups of heart failure that until now had limited data to guide therapies. 1777460220000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/07/14/54/accel-lite-07apr2026 Pulmonary arterial hypertension (PAH) remains a devastating, progressive disease with high morbidity and mortality despite advances in targeted therapies. 1775573940000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-4pm-surviv-acc-2026 Among patients with a failed mitral bioprosthetic valve, transcatheter mitral valve-in-valve (mVIV) treatment was associated with a lower rate of death or disabling stroke at one year compared with standard repeat mitral valve replacement surgery (rMVR), according to results from the SURVIV study presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans. 1774818000000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-1045am-cadence-acc-2026 Sotatercept, an activin signaling inhibitor, was associated with significant improvements in blood pressure and vascular health in patients with heart failure with preserved ejection fraction (HFpEF) and severe combined post and precapillary pulmonary hypertension (CpcPH), according to results of the CADENCE study presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans and simultaneously published in Circulation. 1774800360000 Articles and Stories /Latest-in-Cardiology/Articles/2026/01/28/14/24/eagles-eye-view-28jan2025 In this week’s View, Dr. Eagle looks at exercise systolic blood pressure (SBP) during stress testing related to cardiovascular (CV) events. 1769610360000 Articles and Stories